Form 4: Soleno Therapeutics Merger Completes, Executive Ownership Changes

Soleno Therapeutics, Inc. has completed its merger with Neocrine Biosciences, Inc., resulting in changes to executive beneficial ownership of securities.

Summary

• This filing reports changes in beneficial ownership for Andrew Sinclair, a Director at Soleno Therapeutics Inc. (SLNO).
• The changes are a result of the merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc. (Parent) via Sigma Merger Sub, Inc. (Merger Sub), which became effective on May 18, 2026.
• In connection with the merger, all outstanding vested and unvested Restricted Stock Units (RSUs) were cancelled and converted into the right to receive $53.00 in cash per RSU.
• Similarly, all issued and outstanding shares of Soleno Therapeutics' Common Stock were cancelled and converted into the right to receive $53.00 in cash per share.
• Stock options were also cancelled and converted into a cash payment equal to the difference between the $53.00 Merger Consideration and the option's per-share exercise price, multiplied by the number of shares covered by the option.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for existing shareholders and option holders due to the cash payout, signifying a successful exit.

Positives

• The merger has been successfully completed, providing a cash payout of $53.00 per share for common stock and RSUs.
• Executive stock options are being cashed out, with the value determined by the difference between the merger consideration and the exercise price.

Negatives

• All outstanding equity awards (RSUs and stock options) have been cancelled as part of the merger.
• Shareholders and option holders will receive cash, indicating the end of Soleno Therapeutics as an independent publicly traded entity.

Risks

• The filing does not explicitly mention any ongoing risks or future challenges, as the company is being acquired.

Future Outlook

As Soleno Therapeutics is being acquired, its future outlook is now tied to Neocrine Biosciences, Inc. The filing itself does not provide forward-looking statements for Soleno Therapeutics as an independent entity.

Management Comments

• The filing details the conversion of RSUs and stock options into cash payments as per the merger agreement.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome in the biotechnology and pharmaceutical sector where smaller companies are acquired by larger entities, often providing a liquidity event for shareholders and option holders.

Comparison to Industry Standards

• The $53.00 per share cash consideration is a typical valuation outcome for a merger in the biotech space, reflecting the strategic value of the target company's assets or technology.
• The conversion of stock options into a cash-out based on the difference between the exercise price and the merger consideration is a standard practice in M&A transactions across the industry.

Stakeholder Impact

• Shareholders: Receive $53.00 in cash per share, providing a liquidity event.
• Option Holders: Receive a cash payment based on the intrinsic value of their options at the time of the merger.
• Employees: Those holding RSUs will receive $53.00 in cash per RSU; employees with stock options will receive a cash payout.
• Creditors: The filing does not directly address the impact on creditors, but the acquisition by a larger entity may provide financial stability.

Next Steps

• The merger is complete, and Soleno Therapeutics will operate as a subsidiary of Neocrine Biosciences, Inc.
• Shareholders and option holders will receive their respective cash payments.

Key Dates

Keywords

Soleno Therapeutics, SLNO, Merger, Acquisition, Form 4, Beneficial Ownership, Andrew Sinclair, Neocrine Biosciences, Restricted Stock Units, Stock Options, SEC Filing